Skip to main content
. Author manuscript; available in PMC: 2021 Apr 15.
Published in final edited form as: Cancer Res. 2020 Aug 31;80(20):4552–4564. doi: 10.1158/0008-5472.CAN-20-1418

Figure 5.

Figure 5.

Anti-tumor activity of anti-ALPPL2 ADCs (M25-MC-vc-PAB-MMAF or M25ADCMMAF; and M25-MC-vc-PAB-MMAE or M25ADCMMAE) in vivo. (A) Outline of the experimental design. (B) Nude mice bearing M28 xenografts (~250 mm3) were treated with M25ADCMMAF for a total of 4 doses at 5 mg/kg, along with the two control arms, vehicle only (PBS) and naked antibody (M25 IgG1). Injection days are indicated by black triangles. (C) NSG mice bearing M28 xenograft (~150 mm3) were treated with M25ADCMMAF, CtrlADCMMAF (Ctrl IgG-MC-vc-PAB-MMAF), vehicle only (PBS) and naked antibody (M25 IgG1) at 5 mg/kg for a total of 4 doses. Injection days are indicated by black triangles. Quantification of tumor sizes shows a significant difference (* p < 0.05) at the end of the experiment. Student’s t test, unpaired two-tailed. (D) NSG mice bearing large-sized (~ 500 mm3) M28 xenografts were i.v. injected with M25ADCMMAE, CtrlADCMMAE and vehicle only (PBS) at 5 mg/kg for a total of 4 doses. Injection days are indicated by black triangles. More than 90% reduction of M28 tumor volume was observed. (E) NSG mice bearing M28 xenograft (~ 250 mm3) were treated with M25ADCMMAE or CtrlADCMMAE at 5 mg/kg or 3 mg/kg very four days for a total of 5 doses. Injection days are indicated by black triangles. Complete eradication of M28 tumors was observed in the 5 mg/kg group.